Equities researchers at B. Riley started coverage on shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) in a research note issued on Monday. The brokerage set a “buy” rating and a $5.00 price target on the biopharmaceutical company’s stock. B. Riley’s price objective suggests a potential upside of 65.56% from the company’s current price.

Several other brokerages have also recently issued reports on AVEO. Seaport Global Securities reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a report on Friday, October 6th. Piper Jaffray Companies increased their target price on shares of AVEO Pharmaceuticals from $3.80 to $4.50 and gave the stock an “overweight” rating in a report on Monday, August 28th. BidaskClub upgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 16th. Finally, Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $3.81.

AVEO Pharmaceuticals (NASDAQ:AVEO) opened at $3.02 on Monday. The company has a debt-to-equity ratio of -0.32, a current ratio of 2.33 and a quick ratio of 2.33. AVEO Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $4.24.

COPYRIGHT VIOLATION NOTICE: “AVEO Pharmaceuticals, Inc. (AVEO) Coverage Initiated by Analysts at B. Riley” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/13/aveo-pharmaceuticals-inc-aveo-coverage-initiated-by-analysts-at-b-riley.html.

A number of institutional investors have recently modified their holdings of AVEO. RA Capital Management LLC bought a new position in AVEO Pharmaceuticals during the 2nd quarter worth about $18,727,000. Vanguard Group Inc. lifted its position in shares of AVEO Pharmaceuticals by 48.6% during the second quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after buying an additional 1,162,232 shares during the last quarter. EAM Investors LLC purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at about $1,979,000. Paloma Partners Management Co purchased a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at about $184,000. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of AVEO Pharmaceuticals during the third quarter valued at about $550,000. Institutional investors own 53.94% of the company’s stock.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.